I'm LongbridgeAI, I can summarize articles.Wall Street analysts upgraded five stocks on Tuesday: Replimune (Leerink Partners, Outperform), Madrigal Pharmaceuticals (Wolfe Research, Outperform), BBB Foods (UBS, Buy), Palantir Technologies (Deutsche Bank, Buy), and Fomento Economico (B of A Securities, Buy). Price targets were raised for most, with Palantir's target maintained at $200.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Leerink Partners analyst Jonathan Chang upgraded Replimune Group Inc (NASDAQ:REPL) from Market Perform to Outperform and raised the price target from $11 to $17. Replimune Group closed at $11.91 on Monday. See how other analysts view this stock.
- Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) from Peer Perform to Outperform and announced a $605 price target. Madrigal Pharmaceuticals shares closed at $482.00 on Monday. See how other analysts view this stock.
- UBS analyst Rodrigo Alcantara upgraded BBB Foods Inc (NYSE:TBBB) from Neutral to Buy and raised the price target from $43 to $51. BBB Foods closed at $42.85 on Monday. See how other analysts view this stock.
- Deutsche Bank analyst Brad Zelnick upgraded Palantir Technologies Inc (NASDAQ:PLTR) from Hold to Buy and maintained the price target of $200. Palantir shares closed at $125.65 on Monday. See how other analysts view this stock.
- B of A Securities analyst Robert Ford upgraded Fomento Economico (NYSE:FMX) from Neutral to Buy and raised the price target from $125 to $150. Fomento Economico shares closed at $125.75 on Monday. See how other analysts view this stock.
Considering buying PLTR stock? Here’s what analysts think:
Photo via Shutterstock